Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).
Status:
WITHDRAWN
Trial end date:
2029-04-01
Target enrollment:
Participant gender:
Summary
Aumolertinib (almonertinib; HS-10296) is a novel third-generation EGFR-TKI showing activity against EGFR-sensitizing mutations and EGFR T790M mutation. The third-generation EGFR-TKI osimertinib has been approved in the adjuvant setting. This study is to studying 3-year aumolertinib as adjuvant therapy to see how well it works in treating patients with resected stage IB-IIIA NSCLC harboring sensitizing EGFR mutations.